https://orcid.org/0000-0003-0244-218X
Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jinfan Sun, Shuenqin Hu & Xiuying Li. (2023) Meta-analysis of the prognostic value of soluble programmed death ligand-1 (sPD-L1) in cancers. Biomarkers 28:6, pages 477-485.
Read now
Read now
Rong Fu, Chuan-Qing Jing, Xiu-Rong Li, Zhao-Feng Tan & Hui-Jie Li. (2021) Prognostic Significance of Serum PD-L1 Level in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Combination Cytotoxic Chemotherapy. Cancer Management and Research 13, pages 4935-4946.
Read now
Read now
Saurabh Zanwar & Stephen M. Ansell. (2019) Prognostic significance of PD-L1 and TLR5 expression in peripheral T-cell lymphomas. Leukemia & Lymphoma 60:11, pages 2599-2601.
Read now
Read now
Articles from other publishers (25)
Shruti Kandekar, Sachin Punatar, Navin Khattry, Anant Gokarn, Nishant Jindal, Sumeet Mirgh, Akanksha Chichra, Prashant Tembhare, Pallavi Rane, Jitendra Gawde, Libin Mathew, Anand Patil, Shubhada Chiplunkar & Jyoti Kode. (2023) Low levels of CD26 on certain cellular subtypes of donor harvest is associated with better clinical outcomes post allogeneic stem cell transplantation through regulation of NF-κB pathway and pro-inflammatory cytokines. International Immunopharmacology 125, pages 111054.
Crossref
Crossref
Yanqing Ran, Tingting Wang, Yifei He, Faqiong Zhao & Baizhao Zeng. (2023) Fabrication of electrochemiluminescence aptasensor for PD-L1 detection based on luminescent CdS@Ce-MOF@Au. Microchemical Journal 193, pages 109005.
Crossref
Crossref
Yangyang Ding, Cheng Sun, Linhui Hu, Shudao Xiong & Zhimin Zhai. (2023) Prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in lymphoma: a systematic review and meta-analysis. Annals of Hematology 102:9, pages 2425-2434.
Crossref
Crossref
Yuyan Peng, Li Jiang, Yifan Li & Xiaoping Yu. (2023) Wide-Range SPRi Sensors Based on Aptamer/sPD-L1/anti–PD-L1 Sandwich and AuNPs Enhancement for Ultrasensitive Detection of sPD-L1. Coatings 13:8, pages 1400.
Crossref
Crossref
Aetsam Bin Masood, Sajida Batool, Sajid Nazir Bhatti, Asad Ali, Marian Valko, Klaudia Jomova & Kamil Kuca. (2023) Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiforme—a retrospective cohort study. Frontiers in Immunology 14.
Crossref
Crossref
Sarah Perdikis-Prati, Semira Sheikh, Antonin Bouroumeau & Noémie Lang. (2023) Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review. Biomedicines 11:6, pages 1720.
Crossref
Crossref
Maria Molga-Magusiak, Anna Rzepakowska, Michał Żurek, Iwona Kotuła, Urszula Demkow & Kazimierz Niemczyk. (2023) Prognostic and predictive role of soluble programmed death ligand-1 in head and neck cancer. Brazilian Journal of Otorhinolaryngology 89:3, pages 417-424.
Crossref
Crossref
Seok Jin Kim, Kyung Ju Ryu, Bon Park, Sang Eun Yoon, Junhun Cho, Yoon Park & Won Seog Kim. (2022) Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma. Cancers 14:22, pages 5618.
Crossref
Crossref
Yumi Matsuyama, Kunihiro Asanuma, Keisuke Yoshida, Tomohito Hagi, Takahiro Iino, Tomoki Nakamura & Akihiro Sudo. (2022) The role of soluble CD80 in patients with soft tissue tumors. Journal of Orthopaedic Surgery and Research 17:1.
Crossref
Crossref
Qiang Chen, Junjie Hu, Xiaojun Hu, Kwangnak Koh & Hongxia Chen. (2022) Current methods and emerging approaches for detection of programmed death ligand 1. Biosensors and Bioelectronics 208, pages 114179.
Crossref
Crossref
Xi Chen, Wanchun Wu, Wenwen Wei & Liqun Zou. (2022) Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma. Frontiers in Pharmacology 13.
Crossref
Crossref
Mahlatse C. M. Kgokolo, Katherine Anderson, Shalate C. Siwele, Helen C. Steel, Luyanda L. I. Kwofie, Mike M. Sathekge, Pieter W. A. Meyer, Bernardo L. Rapoport & Ronald Anderson. (2022) Elevated Levels of Soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and Systemic Inflammatory Stress as Potential Contributors to Immune Suppression and Generalized Tumorigenesis in a Cohort of South African Xeroderma Pigmentosum Patients. Frontiers in Oncology 12.
Crossref
Crossref
Honggang Ying, Xiaozhen Zhang, Yi Duan, Mengyi Lao, Jian Xu, Hanshen Yang, Tingbo Liang & Xueli Bai. (2021) Non-cytomembrane PD-L1: An atypical target for cancer. Pharmacological Research 170, pages 105741.
Crossref
Crossref
Julie B. Mortensen, Ida Monrad, Marie B. Enemark, Maja Ludvigsen, Peter Kamper, Mette Bjerre & Francesco d'Amore. (2021) Soluble programmed cell death protein 1 (sPD‐1) and the soluble programmed cell death ligands 1 and 2 (sPD‐L1 and sPD‐L2) in lymphoid malignancies. European Journal of Haematology 107:1, pages 81-91.
Crossref
Crossref
Nur Amira Khairil Anwar, Muhammad Najmi Mohd Nazri, Ahmad Hafiz Murtadha, Elis Rosliza Mohd Adzemi, Venugopal Balakrishnan, Khairul Mohd Fadzli Mustaffa, Tengku Ahmad Damitri Al-Astani Tengku Din, Maya Mazuwin Yahya, Juhara Haron & Noor Fatmawati Mokshtar. (2021) Prognostic prospect of soluble programmed cell death ligand-1 in cancer management. Acta Biochimica et Biophysica Sinica 53:8, pages 961-978.
Crossref
Crossref
Eugene Shenderov, Karim Boudadi, Wei Fu, Hao Wang, Rana Sullivan, Alice Jordan, Donna Dowling, Rana Harb, Joseph Schonhoft, Adam Jendrisak, Michael A. Carducci, Mario A. Eisenberger, James R. Eshleman, Jun Luo, Charles G. Drake, Drew M. Pardoll & Emmanuel S. Antonarakis. (2021) Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial. The Prostate 81:6, pages 326-338.
Crossref
Crossref
Eya Ben Salah, Wahiba Sakly, Coralie Barrera, Sana Mosbahi, Anne‐Pauline Bellanger, Rabeb Farhani, Amine Ksia, Bruno Gottstein, Abdellatif Nouri, Hamouda Babba & Laurence Millon. (2020) Soluble programmed death‐1 (sPD‐1) as predictor of early surgical outcomes of paediatric cystic echinococcosis. Parasite Immunology 43:3.
Crossref
Crossref
Pei Huang, Wei Hu, Ying Zhu, Yushen Wu & Huapeng Lin. (2021) The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis. Frontiers in Oncology 10.
Crossref
Crossref
Xiaoyang Li, Yu Zheng & Fei Yue. (2020) Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis. Targeted Oncology 16:1, pages 13-26.
Crossref
Crossref
Kunihiro Asanuma, Tomoki Nakamura, Akinobu Hayashi, Takayuki Okamoto, Takahiro Iino, Yumiko Asanuma, Tomohito Hagi, Kouji Kita, Kouichi Nakamura & Akihiro Sudo. (2020) Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas. Scientific Reports 10:1.
Crossref
Crossref
Danilo Fiore, Luca Vincenzo Cappelli, Alessandro Broccoli, Pier Luigi Zinzani, Wing C. Chan & Giorgio Inghirami. (2020) Peripheral T cell lymphomas: from the bench to the clinic. Nature Reviews Cancer 20:6, pages 323-342.
Crossref
Crossref
Zane Straume, Justīne Māliņa, Anna Proskurina, Jurijs Nazarovs, Aleksejs Derovs & Patrick Dubois. (2020) T-Cell Lymphoma Misdiagnosed as Crohn’s Disease: Case Report. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences. 74:2, pages 144-149.
Crossref
Crossref
Dhouha Daassi, Kathleen M. Mahoney & Gordon J. Freeman. (2020) The importance of exosomal PDL1 in tumour immune evasion. Nature Reviews Immunology 20:4, pages 209-215.
Crossref
Crossref
Jingrong Qian, Hongxue Meng, Bowen Lv, Jie Wang, Yingying Lu, Wenhui Li & Shu Zhao. (2020) TLR9 expression is associated with PD-L1 expression and indicates a poor prognosis in patients with peripheral T-cell lymphomas. Pathology - Research and Practice 216:3, pages 152703.
Crossref
Crossref
Shujun Liu, Yadi Zhu, Chenxi Zhang, Xiangrui Meng, Bo Sun, Guojun Zhang, Yubo Fan & Xixiong Kang. (2020) The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas. Frontiers in Oncology 10.
Crossref
Crossref